AXSOME THERAPEUTICS (AXSM) Q3 2025 INVESTOR SUMMARY
Financial Performance & Liquidity Axsome reported strong top-line acceleration in Q3 2025, with total revenues reaching $171.0 million (up 63% YoY) and Nine Months (9M) revenue hitting $442.5 million (up 66% YoY). Despite revenue growth, the company remains deeply unprofitable, reporting a Q3 Net Loss of ($47.2 million), though this loss narrowed significantly from (\(64.6M) in Q3 2024. The 9M Net Loss of (\)154.6M) improved upon the prior year’s loss of (\(212.3M). The Accumulated Deficit widened to **\)(1.28 Billion)**. Liq
...